Cardinal Health, Inc. (CAH) is a Dublin, Ohio-based healthcare services and products distributor that supplies pharmaceuticals, medical and laboratory products to pharmacies, hospitals, and other providers. With shares trading near $271.72 after a strong fiscal first-quarter report, investors are asking whether the stock can climb toward a $300 price target. The answer depends on execution in specialty pharmaceuticals, valuation, and whether recent analyst optimism is fully reflected in the share price.
Reviewing roughly a dozen recent, individually attributable analyst targets produced an overall average near $292, spanning approximately $260 to $330. Because that overall mean sits only about 7% above the current price — below the 10% threshold that makes a target meaningful for this exercise — the $300 central target here is the average of the verified targets above the current price, which works out to about $297 before rounding. This is not an official published consensus; independent trackers report similar figures, with S&P Global data near $291 and a FactSet median around $290.
Recent moves cluster in the high $200s to low $300s: UBS raised its target to $310, Morgan Stanley to $306, Baird to $305, RBC Capital to $295, and Mizuho to $290. At the bullish end, Leerink Partners lifted its target to $330, and Evercore ISI adjusted its target to $320. More cautious views include Barclays at $275, Wells Fargo at $277, and Citi and TD Cowen at $280. The spread reflects disagreement about how much premium the market should pay for Cardinal Health's improving mix toward higher-margin specialty distribution.
With shares around $271.72, moving to $300 requires an advance of roughly 10.4% — a modest move by equity-market standards, but one that would take the stock decisively above its recent 52-week high near $286. The path runs through continued execution in the pharmaceutical and specialty-solutions segment, where management raised full-year segment profit growth guidance to 10%–12% from 8%–11% and lifted fiscal 2027 non-GAAP diluted EPS (earnings per share) guidance to $12.80–$13.00 from $12.40–$12.60. GLP-1 medications added about five percentage points to pharmaceutical revenue growth, partly offset by an Inflation Reduction Act headwind.
Cardinal Health's fiscal first-quarter results beat expectations, with adjusted EPS of $3.26 versus a roughly $2.94 consensus and revenue of $67.51 billion, up about 5.5% year over year. The company completed a $500 million share repurchase during the quarter and has renewed contracts covering a large share of revenue, including an extension of its relationship with CVS Health through 2032. Demand strength in generics, oncology, and urology specialty therapies, combined with margin expansion in the pharmaceutical segment, underpins the constructive analyst revisions. A defensive, non-AI business profile has also attracted flows as investors rotate away from crowded technology trades.
The stock trades at a P/E (price-to-earnings ratio) near 35 on trailing earnings, a premium multiple for a low-margin distributor, leaving limited room for multiple expansion. Medical-segment profit is trending toward the low end of its $200–$220 million forecast because of elevated petroleum and commodity costs. Longer-standing overhangs include opioid-related litigation risk and historical segment volatility. If pharmaceutical profit growth decelerates in the middle of the fiscal year as management has signaled, or if the Inflation Reduction Act headwind intensifies, analysts could trim targets rather than raise them.
The recent 52-week high near $286 stands as the nearest meaningful resistance zone; a sustained move above it would open the path toward the psychologically important $300 level. On the downside, support has formed near the $260–$264 area, where shares have found buyers on recent pullbacks. The broader structure remains constructive, with the stock well above its 52-week low near $180, but $300 would represent new all-time-high territory that has not yet been tested.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. The most important upcoming catalysts are the company's quarterly earnings and any further changes to fiscal 2027 guidance, particularly in the pharmaceutical and specialty-solutions segment. Investors should also watch analyst target revisions, medical-segment cost trends, contract renewals, and any regulatory or litigation developments tied to drug pricing or opioids. A sustained break above the prior high near $286 would be the clearest technical confirmation of a move toward $300.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual scanning allows. For investors tracking Cardinal Health and similar names, these signals can add a data-driven layer to fundamental research and help identify when momentum may be turning.
The $300 target for Cardinal Health reflects the average of analyst price targets above the current share price, a figure modestly above the broader all-analyst mean near $292. Reaching it requires roughly 10% upside from about $271.72, which is achievable in principle but not guaranteed. Support comes from raised earnings guidance, specialty and generic demand strength, contract renewals, and a defensive business profile, while a premium valuation, thin margins, medical-segment cost pressure, and litigation overhang are the principal obstacles. With analyst targets spanning $260 to $330, the dispersion shows genuine disagreement about how much the market will pay for the company's improving mix. The next earnings report, guidance updates, and a move through the $286 prior high will be the clearest signals of whether $300 is in reach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CAH has been closely correlated with MCK. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAH jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To CAH | 1D Price Change % | ||
|---|---|---|---|---|
| CAH | 100% | -0.33% | ||
| MCK - CAH | 72% Closely correlated | -0.66% | ||
| COR - CAH | 62% Loosely correlated | -0.64% | ||
| HSIC - CAH | 7% Poorly correlated | +3.32% | ||
| AHG - CAH | 4% Poorly correlated | +3.17% | ||
| FOCL - CAH | 2% Poorly correlated | +9.15% | ||
More | ||||